Analysts expect Timbercreek Financial Corporation (TSE:TF) to report $0.19 EPS on February, 27.T_TF’s profit would be $14.94 million giving it 12.08 P/E if the $0.19 EPS is correct. After having $0.18 EPS previously, Timbercreek Financial Corporation’s analysts see 5.56% EPS growth. The stock increased 0.66% or $0.06 during the last trading session, reaching $9.18. About 80,281 shares traded. Timbercreek Financial Corporation (TSE:TF) has 0.00% since February 17, 2017 and is . It has underperformed by 16.70% the S&P500.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. The company has market cap of $103.07 million. The Company’s principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration . It has a 1.79 P/E ratio. The firm is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD.
Among 3 analysts covering Timbercreek Financial (TSE:TF), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Timbercreek Financial had 5 analyst reports since November 11, 2016 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, March 2 by TD Securities. Raymond James maintained the stock with “Outperform” rating in Friday, March 3 report. The rating was maintained by TD Securities on Friday, November 11 with “Buy”. National Bank Canada maintained the stock with “Outperform” rating in Wednesday, November 16 report.
Timbercreek Financial Corporation, a non-bank commercial real estate lender, provides shorter-duration structured financing solutions to commercial real estate investors in Canada. The company has market cap of $721.69 million. It focuses on lending against income-producing real estate properties, such as multi-residential, office, and retail buildings located in urban markets. It has a 13.13 P/E ratio.
Armistice Capital Llc holds 1.12% of its portfolio in Ophthotech Corporation for 3.36 million shares. Bogle Investment Management L P De owns 448,841 shares or 0.09% of their US portfolio. Moreover, Dafna Capital Management Llc has 0.09% invested in the company for 50,000 shares. The California-based Regents Of The University Of California has invested 0.09% in the stock. Nine Chapters Capital Management Llc, a New Jersey-based fund reported 13,500 shares.
Ratings analysis reveals 0 of Ophthotech’s analysts are positive. Out of 6 Wall Street analysts rating Ophthotech, 0 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. OPHT was included in 6 notes of analysts from December 12, 2016. Chardan Capital Markets downgraded the stock to “Neutral” rating in Monday, December 12 report. The firm has “Neutral” rating by Citigroup given on Monday, December 12. The stock of Ophthotech Corporation (NASDAQ:OPHT) has “Neutral” rating given on Tuesday, December 13 by Goldman Sachs. As per Monday, December 12, the company rating was downgraded by JP Morgan. Leerink Swann downgraded the stock to “Mkt Perform” rating in Monday, December 12 report. The firm has “Hold” rating by Gabelli given on Tuesday, December 13.
Analysts await Ophthotech Corporation (NASDAQ:OPHT) to report earnings on February, 27. They expect $-0.58 earnings per share, up 68.82% or $1.28 from last year’s $-1.86 per share. After $5.25 actual earnings per share reported by Ophthotech Corporation for the previous quarter, Wall Street now forecasts -111.05% negative EPS growth.
The stock increased 2.88% or $0.08 during the last trading session, reaching $2.86. About 335,721 shares traded. Ophthotech Corporation (OPHT) has declined 94.82% since February 17, 2017 and is downtrending. It has underperformed by 111.52% the S&P500.
Since January 1, 0001, it had 0 buys, and 8 sales for $108,250 activity.